Our Treatments

Medicine We Develop

Current Developments
Oral for IBDCrohn's & Colitis
Topical for Psoriasis
Our treatments

Creating Better Treatments and Changing Lives

EPM is committed to developing a series of new therapeutic solutions based on cannabinoid acids which provide alternative treatments for patients. This is the driving force behind EPM’s research program. Although cannabinoid acids are potential treatments for a wide range of diseases, currently, EPM focuses on three main therapeutic conditions based on its lead molecule EPM301: Inflammatory Bowel Disease and inflammatory skin disease (psoriasis).

Oral formulationCrohn's & Colitis
Phase 1 Clinical trial in 2023
Patients in Europe
Our Treatments

Inflammatory Bowel Disease

Selected formulation
Oral

Expected clinical trail timeline
Phase 1 clinical trail in healthy volunteers anticipated in 2023

EPM's potential solution
The treatment is based on EPM301 and has been evaluated in both acute (DSS induced mouse colitis) and chronic (IL-10 knock-out mouse) animal models of IBD and has shown similar activity to prednisone (acute model) and anti-TNFa mAb (chronic model) when administered by gavage.

Topical formulationPsoriasis
Phase 1 Clinical trial during 2023
Patients worldwide
Our treatments

Psoriasis

Selected formulation
Topical

Expected clinical trail timeline
Phase 1 clinical trail in healthy volunteers anticipated during 2023

EPM's potential solution
The treatment is based on EPM301 and has been evaluated in an ex vivo model of inflammatory skin disease. When applied topically, it displayed similar activity to hydrocortisone.